Pierre Jacquet - Feb 5, 2025 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role
Director
Signature
/s/ Christine Fox, by power of attorney
Stock symbol
MREO
Transactions as of
Feb 5, 2025
Transactions value $
$0
Form type
4
Date filed
2/6/2025, 04:30 PM
Previous filing
Feb 9, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MREO Share Options (Right to buy) Award $0 +55K $0.00 55K Feb 5, 2025 American Depositary Shares 55K $3.16 Direct F1, F2
transaction MREO Deferred Restricted Stock Units Award +15.2K 15.2K Feb 5, 2025 American Depository Shares 15.2K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date
F2 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer
F3 Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.